Literature DB >> 25896311

Glycyrrhizin Attenuates Proinflammatory Cytokines through a Peroxisome Proliferator-Activated Receptor-γ-Dependent Mechanism and Experimental Vasospasm in a Rat Model.

Chih-Zen Chang1, Shu-Chuan Wu, Aij-Lie Kwan.   

Abstract

The peroxisome proliferator-activated receptor (PPAR) is downregulated in the cortex of experimental subarachnoid hemorrhage (SAH) animals. This study is to examine the effect of glycyrrhizin on the alternation of PPARs and proinflammatory cytokines in a rodent SAH model. CSF cytokines were evaluated by RT-PCR. Basilar arteries (BAs) were harvested to examine PPARs (RT-PCR and Western blot), and a morphological examination was conducted. Deformed endothelium and tortuous elastic lamina were observed in the BAs of the SAH groups, but they were absent in the glycyrrhizin groups or the healthy controls. The PPAR-γ and -δ protein levels were reduced in the SAH groups (p < 0.01). Glycyrrhizin significantly increased the expressed PPAR-γ protein and mRNA (preconditioning) and PPAR-δ mRNA (both treatment and preconditioning), which corresponded to the reduced IL-1β and TNF-α levels. The administration of a PPAR-γ inhibitor, BADGE, halted the reduction of IL-1β and TNF-α in the glycyrrhizin groups. Conclusively, glycyrrhizin exerts anti-inflammatory effects on SAH-induced vasospasm and attenuates the expression of PPARs, especially PPAR-γ, which corresponds to the severity of SAH-related inflammation. These findings also offer credit to the antivasospastic effect of glycyrrhizin and its vasculoprotective effect in animals subjected to SAH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896311     DOI: 10.1159/000381099

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  8 in total

1.  Mangiferin Inhibits IL-1β-Induced Inflammatory Response by Activating PPAR-γ in Human Osteoarthritis Chondrocytes.

Authors:  Yanlong Qu; Li Zhou; Chunlei Wang
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 2.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

3.  Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.

Authors:  Takashi Yamashita; Yoshihide Asano; Takashi Taniguchi; Kouki Nakamura; Ryosuke Saigusa; Shunsuke Miura; Tetsuo Toyama; Takehiro Takahashi; Yohei Ichimura; Ayumi Yoshizaki; Maria Trojanowska; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2016-10-21       Impact factor: 8.551

4.  Ethyl pyruvate attenuates delayed experimental cerebral vasospasm following subarachnoid haemorrhage in rats: possible role of JNK pathway.

Authors:  Ke Jin; Hui Wu; Tao Lv; Jiong Dai; Xiaohua Zhang; Yichao Jin
Journal:  RSC Adv       Date:  2018-02-16       Impact factor: 4.036

Review 5.  HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

6.  mRNA Expression Profiles from Whole Blood Associated with Vasospasm in Patients with Subarachnoid Hemorrhage.

Authors:  Huichun Xu; Boryana Stamova; Bradley P Ander; Ben Waldau; Glen C Jickling; Frank R Sharp; Nerissa U Ko
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

7.  Peroxisome proliferator‑activated receptor β/δ regulates cerebral vasospasm after subarachnoid hemorrhage via modulating vascular smooth muscle cells phenotypic conversion.

Authors:  Li Xu; Jiang Wu; Yuan Liu; Gang Chen; Chao Ma; Hongrong Zhang
Journal:  Mol Med Rep       Date:  2021-10-19       Impact factor: 2.952

Review 8.  Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.

Authors:  Ayesheh Enayati; Mobina Ghojoghnejad; Basil D Roufogalis; Seyed Adel Maollem; Amirhossein Sahebkar
Journal:  PPAR Res       Date:  2022-08-31       Impact factor: 4.385

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.